RecentRCT

ADA-HF

ADA-HF: acetazolamide as a chloride sparing diuretic in patients admitted to hospital with heart failure.

Clinical research in cardiology : official journal of the German Cardiac Society, 2026 · Single-center randomized open-label trial

Population: 46 adults in a single-center open-label trial
Intervention: Oral acetazolamide 250 mg twice daily plus IV furosemide 240 mg/day
Comparator: IV furosemide alone
Primary outcome: Daily net fluid loss and chloride change through day four
Result: No significant extra net fluid loss (P=.51); chloride was preserved, with frequent adverse effects and imprecise safety comparisons.

What the trial found

No significant extra net fluid loss (P=.51); chloride was preserved, with frequent adverse effects and imprecise safety comparisons.

Clinical interpretation

Different regimen/design from ADVOR; chloride benefit is not proven clinical-outcome benefit.

Moderate certainty

Clinical Context & Relevant Topics (2)

Disease Reference

Acute Heart Failure & Cardiogenic Congestion

Hemodynamic phenotypes (SCAPE vs ADHF vs Cardiogenic Shock), non-invasive positive pressure ventilation, high-dose vasodilator algorithms, loop diuretics, and sequential nephron blockade.

View Topic Context →

Acute Cardiogenic Pulmonary Edema & SCAPE

Hydrostatic pulmonary edema physiology, SCAPE vs decompensated HF vs cardiogenic shock, NIV, titrated vasodilators when hypertensive, diuresis, and sequential nephron blockade.

View Topic Context →